Literature DB >> 9686307

Structural and kinetic features of amyloid beta-protein fibrillogenesis.

D B Teplow1.   

Abstract

Alzheimer's disease (AD) is an archetype of a class of diseases characterized by abnormal protein deposition. In each case, deposition manifests itself in the form of amyloid deposits composed of fibrils of otherwise normal, soluble proteins or peptides. An ever-increasing body of genetic, physiologic, and biochemical data supports the hypothesis that fibrillogenesis of the amyloid beta-protein is a seminal event in Alzheimer's disease. Inhibiting A beta fibrillogenesis is thus an important strategy for AD therapy. However, before this strategy can be implemented, a mechanistic understanding of the fibrillogenesis process must be achieved and appropriate steps selected as therapeutic targets. Following a brief introduction to AD, I review here the current state of knowledge of A beta fibrillogenesis. Special emphasis is placed on the morphologic, structural, and kinetic aspects of this complex process.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9686307     DOI: 10.3109/13506129808995290

Source DB:  PubMed          Journal:  Amyloid        ISSN: 1350-6129            Impact factor:   7.141


  57 in total

1.  Effects of the English (H6R) and Tottori (D7N) familial Alzheimer disease mutations on amyloid beta-protein assembly and toxicity.

Authors:  Kenjiro Ono; Margaret M Condron; David B Teplow
Journal:  J Biol Chem       Date:  2010-05-07       Impact factor: 5.157

2.  Investigating how peptide length and a pathogenic mutation modify the structural ensemble of amyloid beta monomer.

Authors:  Yu-Shan Lin; Gregory R Bowman; Kyle A Beauchamp; Vijay S Pande
Journal:  Biophys J       Date:  2012-01-18       Impact factor: 4.033

3.  Association thermodynamics and conformational stability of beta-sheet amyloid beta(17-42) oligomers: effects of E22Q (Dutch) mutation and charge neutralization.

Authors:  Nikolay Blinov; Lyudmyla Dorosh; David Wishart; Andriy Kovalenko
Journal:  Biophys J       Date:  2010-01-20       Impact factor: 4.033

4.  On the nucleation of amyloid beta-protein monomer folding.

Authors:  Noel D Lazo; Marianne A Grant; Margaret C Condron; Alan C Rigby; David B Teplow
Journal:  Protein Sci       Date:  2005-06       Impact factor: 6.725

5.  Alzheimer's disease: halothane induces Abeta peptide to oligomeric form--solution NMR studies.

Authors:  Pravat K Mandal; Jay W Pettegrew; Dennish W McKeag; Ratna Mandal
Journal:  Neurochem Res       Date:  2006-06-29       Impact factor: 3.996

6.  Chronic Sleep Restriction Induces Cognitive Deficits and Cortical Beta-Amyloid Deposition in Mice via BACE1-Antisense Activation.

Authors:  Hong-Yi Zhao; Hui-Juan Wu; Jia-Lin He; Jian-Hua Zhuang; Zhen-Yu Liu; Liu-Qing Huang; Zhong-Xin Zhao
Journal:  CNS Neurosci Ther       Date:  2017-02-01       Impact factor: 5.243

7.  Expression and purification of amyloid-beta peptides from Escherichia coli.

Authors:  Kanchan Garai; Scott L Crick; Sourajit M Mustafi; Carl Frieden
Journal:  Protein Expr Purif       Date:  2009-02-20       Impact factor: 1.650

8.  Effects of grape seed-derived polyphenols on amyloid beta-protein self-assembly and cytotoxicity.

Authors:  Kenjiro Ono; Margaret M Condron; Lap Ho; Jun Wang; Wei Zhao; Giulio M Pasinetti; David B Teplow
Journal:  J Biol Chem       Date:  2008-09-24       Impact factor: 5.157

9.  Role of water in mediating the assembly of Alzheimer amyloid-beta Abeta16-22 protofilaments.

Authors:  Mary Griffin Krone; Lan Hua; Patricia Soto; Ruhong Zhou; B J Berne; Joan-Emma Shea
Journal:  J Am Chem Soc       Date:  2008-07-29       Impact factor: 15.419

10.  The structures of the E22Δ mutant-type amyloid-β alloforms and the impact of E22Δ mutation on the structures of the wild-type amyloid-β alloforms.

Authors:  Orkid Coskuner; Olivia Wise-Scira; George Perry; Taizo Kitahara
Journal:  ACS Chem Neurosci       Date:  2012-12-18       Impact factor: 4.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.